ORAL LOW-DOSE ETOPOSIDE THERAPY FOR REFRACTORY MULTIPLE-MYELOMA WITH EXTRAMEDULLARY INVOLVEMENT

被引：2
作者：
KATO, Y
TAKEDA, H
MIHARA, H
KOBAYASHI, H
KAMIJIMA, S
KUWAHARA, M
OGURI, T
NAGASAKA, T
机构：
[1] Second Department of Internal Medicine, Aichi Medical College, Aichi
[2] Division of Pathology, Clinical Laboratory, Nagoya University Hospital, Nagoya
来源：
INTERNAL MEDICINE | 1995年 / 34卷 / 10期
关键词：
VP-16; ORAL ADMINISTRATION; REFRACTORY PLASMACYTOMA;
D O I：
10.2169/internalmedicine.34.1023
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A 65-year-old man was hospitalized with IgG kappa-type multiple myeloma (MM) and enormous subcutaneous plasmacytomas. Two different combination chemotherapy regimens (MMCP and AVPP) and alpha-interferon therapy were ineffectual. Oral administration of etoposide at 50 mg/day was subsequently started, the tumors completely disappeared after 5 months, The blood level of monoclonal protein became undetectable after 8 months of continuous treatment, The side effect noted was loss of hair. The course in this patient suggests that long-term daily low-dose administration of etoposide should be attempted in patients with refractory MM and extramedullary plasmacytoma.
引用
收藏
页码：1023 / 1026
页数：4
相关论文
共 16 条
  • [1] Kyle R.A., Multiple myeloma: An update on diagnosis and management, Acta Oncol, 29, (1990)
  • [2] Hainsworth J.D., Johonson D.H., Frazier S.R., Greco F.A., Chronic daily administration of oral etoposide in refractory lymphoma, Eur J Cancer, 26, (1990)
  • [3] Tokiwa F., Utunomiya A., Nakahara K., Et al., A case of refractory multiple myeloma effectively treated with long-term oral etoposide, Gan To Kagakuryoho, 20, (1993)
  • [4] Knowiling M.A., Harwood A.R., Bergsagel D.E., Comparison of extramedullary plasmacytoma with solitary and multiple plasma cell tumors of bone, J Clin Oncol, 1, (1983)
  • [5] Bauduer F., Tanguy A., Mandard A.M., Plasmacytoma with asynchronous metastasis, Arch Anat Cytol Pathol, 40, (1992)
  • [6] Wiltshaw E., The natural history of extramedullary plasmacytoma and its relation to solitary myeloma of bone and myelomatosis, Medicine, 55, (1976)
  • [7] Foucar K., Raber M., Foucar E., Et al., Anaplastic myeloma with massive extramedullary involvement, Cancer, 51, (1983)
  • [8] Jowitt S.N., Jacobs A., Batman P.A., Sapherson D.A., Atypical progression of multiple myeloma with extensive extramedullary disease, J Clin Pathol, 47, (1994)
  • [9] Pilarski L.M., Belch A.R., Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma, Blood, 83, (1994)
  • [10] Latreille J., Barlogie B., Johnston D., Drewinko B., Alexanian R., Ploidy, proliferative characteristics in monoclonal gammopathies, Blood, 59, (1982)
12